Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories (the “Issuer”), today announces that it has
completed a capital increase of €150k, by way of a private
placement.
This transaction continues the path initiated by the company at
the beginning of 2024 to enlarge its shareholder base via selected
transactions, while strengthening its financial resources. The net
proceeds of this issue, amounting to €150k, will support the
company’s working capital needs and extend its financial
visibility.
Legal terms of the Capital Increase
The implementation of this capital increase, carried out with
cancellation of shareholders' subscription rights through a private
placement, was approved by the Board of Directors of the Issuer at
its meeting held on August 13, 2024 (the "Capital
Increase").
The new shares will be issued on the basis of the 8th resolution
of the Issuer's shareholders' meeting held on June 28, 2023. The
settlement-delivery of the new shares will take place on August 19,
2024.
The Capital Increase did not require the approval of a notice
(“prospectus”) by the Autorité des marchés financiers (the
“AMF”).
Main terms of the Capital Increase
The Issuer has issued a total of 100,000 new ordinary shares,
with a par value of €0.5 each, to the investor, pursuant to article
L. 411-2 1° of the French Monetary and Financial Code, in
accordance with the 8th resolution passed by its Annual General
Meeting on June 28, 2023.
The issuance price of the new shares issued under the Capital
Increase, equal to €1.5 per share, represents a premium of
approximately 3% on the Ikonisys share price at the close of August
14, 2024.
Impact of the transaction in terms of liquidity risk
management and financing horizon
As of December 31, 2023, and as mentioned in the financial
report published on July 8, 2024, the Issuer's consolidated cash
position amounted to €9.4k.
In order to strengthen its financial resources, Ikonisys
completed a capital increase of €1m on December 28, 2023 and more
recently two capital increases for a total cumulative sum of €400k
on June and July 2024.
Taking into account these elements, the Capital Increase
completed and the previously secured financing facility, the
Company considers that it is now in a position to meet its
financing needs for more than 12 months.
Impact of the Capital Increase on a shareholder holding 1% of
the capital
On the basis of the 10,718,090 shares outstanding, the impact on
the shareholding of a shareholder holding 1% of the Issuer's
capital prior to the transaction is as follows:
On a non-diluted basis
On a diluted basis1
Before completion of the Capital
Increase
1.00%
0.96 %
After issuance of the 166,666 shares
resulting from the Capital Increase
0.99 %
0.96 %
1 Dilution takes into account the exercise of all outstanding
dilutive instruments likely to result in the issuance of a maximum
indicative number of 397,043 new shares.
Capital breakdown before and after completion of the Capital
Increase
Before the Capital Increase:
Shareholder
Number of shares
% of share capital and voting
rights
Cambria Co-Investment Fund
5,268,989
49.16%
Cambria Equity Partners
2,074,049
19.35%
MC Consulting*
351,464
3.28%
Free float
3,023,588
28.21%
Total
10,718,090
100.00%
*Holding company of the CEO, Mario Crovetto
After the Capital Increase:
Shareholder
Number of shares
% of share capital and voting
rights
Cambria Co-Investment Fund
5,268,989
48.71%
Cambria Equity Partners
2,074,049
19.17%
MC Consulting*
351,464
3.25%
Free float
3,123,588
28.87%
Total
10,818,090
100.00%
*Holding company of the CEO, Mario Crovetto
Risk factors related to the Issuer
Detailed information about the Issuer, including its business,
financial information, results, outlook and related risk factors,
is contained in the 2023 annual financial report for the financial
year ended December 31, 2023, published on July 8, 2024. This
document, together with other regulated information and all the
Issuer's press releases, is available on the Issuer's website
(www.ikonisys-finance.com).
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to www.ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240814608188/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024